<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03301168</url>
  </required_header>
  <id_info>
    <org_study_id>BP-U-004</org_study_id>
    <nct_id>NCT03301168</nct_id>
  </id_info>
  <brief_title>Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant</brief_title>
  <official_title>Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bellicum Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bellicum Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate pediatric patients with malignant or non-malignant blood cell&#xD;
      disorders who are having a blood stem cell transplant depleted of T cell receptor (TCR) alfa&#xD;
      and beta cells that comes from a partially matched family donor. The study will assess&#xD;
      whether immune cells, called T cells, from the family donor, that are specially grown in the&#xD;
      laboratory and given back to the patient along with the stem cell transplant can help the&#xD;
      immune system recover faster after transplant. As a safety measure these T cells have been&#xD;
      programmed with a self-destruct switch so that they can be destroyed if they start to react&#xD;
      against tissues (graft versus host disease).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1/2 study evaluating the safety and feasibility of BPX-501 T cells infused&#xD;
      after partially mismatched, related, TCR alpha beta T cell depleted hematopoietic stem cell&#xD;
      transplant (HSCT) in pediatric patients. The purpose of this clinical trial is to determine&#xD;
      whether BPX-501 infusion can enhance immune reconstitution in those patients with hematologic&#xD;
      disorders, with the potential for reducing the severity and duration severe acute graft&#xD;
      versus host disease (GvHD).&#xD;
&#xD;
      The trial will also evaluate the treatment of GvHD by the infusion of dimerizer drug&#xD;
      (AP1903/rimiducid) in those subjects who present with GVHD that does not adequately respond&#xD;
      to standard of care therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Anticipated">May 2034</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>Month 24</time_frame>
    <description>Demonstrate safety of BPX-501 MTD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TRM/NRM</measure>
    <time_frame>Day 180, Month 12</time_frame>
    <description>Assess the cumulative incidence of non-relapse/transplant related mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Month 24</time_frame>
    <description>Disease-free survival rates after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>Month 12</time_frame>
    <description>Cumulative incidence of relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment</measure>
    <time_frame>Month 24</time_frame>
    <description>Cumulative incidence of neutrophil and platelet engraftment, primary &amp; secondary graft failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GvHD</measure>
    <time_frame>Month 24</time_frame>
    <description>Cumulative incidence and severity of acute and chronic GvHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rimiducid Efficacy</measure>
    <time_frame>Month 24</time_frame>
    <description>Time to resolution of acute or chronic GvHD after administration of rimiducid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection</measure>
    <time_frame>Month 24</time_frame>
    <description>Rate of infectious complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations</measure>
    <time_frame>Month 24</time_frame>
    <description>Duration of hospitalization and rehospitalization</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Leukemia, Acute Myeloid (AML), Child</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Primary Immune Deficiency Disorder</condition>
  <condition>Osteopetrosis</condition>
  <condition>Cytopenia</condition>
  <condition>Hemoglobinopathy in Children</condition>
  <condition>Anemia, Aplastic</condition>
  <arm_group>
    <arm_group_label>BPX-501 T cells and Rimiducid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TCR alpha beta depleted graft infusion with addback of BPX-501 T cells.&#xD;
Rimiducid: Dimerizer drug administered to subjects who present with Grade I-IV acute GVHD with inadequate response to steroids within 48 hours of treatment or mild to severe chronic GVHD with inadequate response to steroids within 7 days of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BPX-501 T cells</intervention_name>
    <description>T cells transduced with CaspaCIDe® safety switch</description>
    <arm_group_label>BPX-501 T cells and Rimiducid</arm_group_label>
    <other_name>rivogenlecleucel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rimiducid</intervention_name>
    <description>administered to inactivate BPX-501 cells in the event of GVHD</description>
    <arm_group_label>BPX-501 T cells and Rimiducid</arm_group_label>
    <other_name>AP1903</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 1 month and &lt; 26 years&#xD;
&#xD;
          2. Life expectancy &gt; 10 weeks&#xD;
&#xD;
          3. Subjects deemed eligible for allogeneic stem cell transplantation.&#xD;
&#xD;
          4. Subjects with life-threatening hematological malignancies (high-risk ALL in 1st CR,&#xD;
             ALL in 2nd or subsequent CR, AML in 1st CR, AML in 2nd or subsequent CR,&#xD;
             myelodysplastic syndromes, non-Hodgkin lymphomas in 2nd or subsequent CR, other&#xD;
             hematologic malignancies eligible for stem cell transplantation per institutional&#xD;
             standard);&#xD;
&#xD;
          5. Non-malignant disorders amenable to cure by an allograft:&#xD;
&#xD;
               1. primary immune deficiencies,&#xD;
&#xD;
               2. severe aplastic anemia not responding to immune suppressive therapy,&#xD;
&#xD;
               3. osteopetrosis,&#xD;
&#xD;
               4. hemoglobinopathies, (thalassemias, and sickle cell anemia, and Diamond-Blackfan&#xD;
                  anemia among others)&#xD;
&#xD;
               5. congenital/hereditary cytopenia, including Fanconi Anemia before any clonal&#xD;
                  malignant evolution (MDS, AML) Note: Subjects will be eligible if they meet&#xD;
                  either item 4 OR item 5.&#xD;
&#xD;
          6. Lack of suitable conventional donor (HLA identical sibling or HLA phenotypically&#xD;
             identical relative or 10/10 unrelated donor evaluated using high resolution molecular&#xD;
             typing) or presence of rapidly progressive disease not permitting time to identify an&#xD;
             unrelated donor&#xD;
&#xD;
          7. A minimum genotypic identical match of 5/ 10 is required.&#xD;
&#xD;
          8. The donor and recipient must be identical, as determined by high resolution typing, at&#xD;
             least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-&#xD;
             DRB1 and HLA-DQB1.&#xD;
&#xD;
          9. Lansky/Karnofsky score &gt; 50&#xD;
&#xD;
         10. Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Greater than Grade II acute GVHD or chronic extensive GVHD due to a previous allograft&#xD;
             at the time of inclusion&#xD;
&#xD;
          2. Subject receiving an immunosuppressive treatment for GVHD treatment due to a previous&#xD;
             allograft at the time of inclusion&#xD;
&#xD;
          3. Dysfunction of liver (ALT/AST &gt; 5 times normal value, or bilirubin &gt; 3 times normal&#xD;
             value), or of renal function (creatinine clearance &lt; 30 mL / min)&#xD;
&#xD;
          4. Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive&#xD;
             heart failure or left ventricular ejection fraction &lt; 40%)&#xD;
&#xD;
          5. Current active infectious disease (including positive HIV serology or viral RNA)&#xD;
&#xD;
          6. Serious concurrent uncontrolled medical disorder&#xD;
&#xD;
          7. Pregnant or breastfeeding subject&#xD;
&#xD;
          8. For subjects who have received more than 1 x 10E5 alpha/beta T cells/kg with the graft&#xD;
             infusion the clinical trial site must contact the sponsor for approval to be eligible&#xD;
             to receive BPX-501 infusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bellicum Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Bellicum Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University; Division of Pediatric Stem Cell Transplant &amp; Regenerative Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Boston Children's Cancer and Blood Disorders Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital at Montefiore</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University - Doernbecher Children's Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern-Children's Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>77390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/ Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 29, 2017</study_first_submitted>
  <study_first_submitted_qc>October 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2017</study_first_posted>
  <last_update_submitted>October 1, 2020</last_update_submitted>
  <last_update_submitted_qc>October 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALL</keyword>
  <keyword>AML</keyword>
  <keyword>hematologic neoplasms</keyword>
  <keyword>hematologic malignancies</keyword>
  <keyword>primary immune deficiences</keyword>
  <keyword>allogeneic stem cell transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Osteopetrosis</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Hemoglobinopathies</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Primary Immunodeficiency Diseases</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

